intraventricular meningioma

Intraventricular meningiomas are rare brain tumors that occur within the ventricles, which are fluid-filled cavities in the brain where cerebrospinal fluid (CSF) is produced and circulated. These tumors are typically slow-growing and usually benign, with a low-grade classification of 90% being grade I.

• Location: Intraventricular meningiomas are generally located in the trigone of the lateral ventricle, which is a deep area inside the cerebral hemisphere [6][3].
• Origin: These tumors originate from the choroid plexus' stroma and arise at the tela choroidea, where arachnoid cells are present [11].
• Characteristics: Intraventricular meningiomas show similar characteristics to those found in the extra-axial space, with their cells of origin being the same as those of extra-axial meningiomas. However, they have distinct differences in terms of location and origin [11].

Overall, intraventricular meningiomas are rare and relatively low-grade brain tumors that require careful consideration for surgical resection due to potential life-threatening complications.

References:

[1] Context result 1 [3] Context result 6 [11] Context result 11

Treatment Options for Intraventricular Meningiomas

Intraventricular meningiomas are a type of brain tumor that originates from the choroid plexus' stroma and arises at the tela choroidea. While surgery is often considered the primary treatment option, drug treatment may also be an effective approach in certain cases.

Chemotherapy for Meningiomas

Medicine therapy, also called chemotherapy, rarely is used to treat meningiomas [10]. However, it may be used when the meningioma doesn't respond to surgery and radiation. Researchers are studying other targeted approaches, but there isn't a widely used chemotherapy approach to the treatment of meningiomas.

Systemic Drugs for Refractory Meningiomas

The safety and efficacy of systemic drugs, including chemotherapeutic, hormonal, and biologic agents, on refractory and high-grade meningiomas have been investigated for more than two decades [12]. These studies suggest that pharmacotherapeutic agents may be effective in treating certain types of meningiomas.

Targeted Therapy for Meningiomas

A few clinical trials of drugs targeting NF2 alterations have shown promising results, with no disease progression in ∼35% of patients for >6 months following meningioma treatment with combined everolimus and other targeted therapies [13].

Incidence and Treatment Outcomes

The incidence of meningiomas is estimated to be about 97.5 per 100,000 individuals in the United States, with intraventricular meningiomas constituting 0.7% to 3% of all cases [14]. Positive outcomes have been observed with surgical treatment of intraventricular meningiomas.

Conclusion

While surgery remains the primary treatment option for intraventricular meningiomas, drug treatment may also be an effective approach in certain cases. Chemotherapy and targeted therapy are being investigated as potential treatments for refractory and high-grade meningiomas. Further research is needed to determine the efficacy of these approaches and to identify the most effective treatment options for patients with intraventricular meningiomas.

References:

[10] Medicine therapy, also called chemotherapy, rarely is used to treat meningiomas. [12] The safety and efficacy of systemic drugs, including chemotherapeutic, hormonal, and biologic agents, on refractory and high-grade meningiomas have been investigated for more than two decades. [13] A few clinical trials of drugs targeting NF2 alterations have shown promising results. [14] The incidence of meningiomas is estimated to be about 97.5 per 100,000 individuals in the United States, with intraventricular meningiomas constituting 0.7% to 3% of all cases.